Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection
Angiotensin-converting enzyme 2 (ACE2), the host cell-binding site for SAR-CoV-2, poses two-fold drug development problems. First, the role of ACE2 itself is still a matter of investigation, and no specific drugs are available targeting ACE2. Second, as a consequence of SARS-CoV-2 interaction with A...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR (Innovative Medical Research) Press Limited
2020-09-01
|
| Series: | Reviews in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://rcm.imrpress.com/fileup/2153-8174/PDF/1601436628011-1720097959.pdf |